Sarah Cullen
Family · Norfolk, VANPI 1215546429
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,139 of the $16,425 with a category attached, or 67.8%. AbbVie accounts for 79.1% of it on its own, with 35 other manufacturers making up the rest. Among family clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 292 payments — averaging $56.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$13K
- Lundbeck LLC$847
- Pfizer$419
- Nevro Corp.$314
- Merz Pharmaceuticals, LLC$259
- Lilly USA, LLC$136
- plus $1K from 30 others
What the payments were for
- Speaking & faculty fees$11,13968%
- Travel & lodging$1211%
- Food & beverage$5,16631%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 143 | $12,990 |
| Lundbeck LLC | 33 | $847 |
| Pfizer | 26 | $419 |
| Nevro Corp. | 4 | $314 |
| Merz Pharmaceuticals, LLC | 9 | $259 |
| Lilly USA, LLC | 8 | $136 |
| Almatica Pharma LLC | 7 | $111 |
| Fidia Pharma USA Inc. | 4 | $107 |
| Amgen | 4 | $96 |
| Bioventus LLC | 3 | $91 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $79 |
| IBSA Pharma Inc. | 3 | $74 |
| Kowa Pharmaceuticals America, Inc. | 5 | $72 |
| SPR Therapeutics, Inc | 3 | $71 |
| Relievant Medsystems, Inc. | 1 | $58 |
| Merck | 3 | $56 |
| Globus Medical | 1 | $49 |
| Abbott | 2 | $44 |
| Collegium Pharmaceutical, Inc. | 2 | $44 |
| Azurity Pharmaceuticals, Inc. | 2 | $44 |
| Vertex | 2 | $42 |
| GRT US Holding, Inc. | 2 | $38 |
| Si-bone, Inc. | 2 | $37 |
| Avanos Medical | 2 | $36 |
| Avanir Pharmaceuticals, Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Hikma Pharmaceuticals USA | 2 | $32 |
| Curonix LLC | 1 | $32 |
| Currax Pharmaceuticals LLC | 2 | $27 |
| Biogen | 1 | $27 |
| Biohaven Pharmaceuticals, Inc. | 1 | $25 |
| Medtronic | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Impel Pharmaceuticals Inc. | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Averitas Pharma Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,425 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QuliptaAtogepant | 26 | $39,553 |
| UbrelvyUbrogepant | 19 | $34,511 |
| Nucynta ErTapentadol Hcl | 24 | $33,232 |
| BelbucaBuprenorphine Hcl | 25 | $20,744 |
| Buprenorphine | 42 | $10,702 |
| Xtampza ErOxycodone Myristate | 11 | $7,714 |
| Diclofenac Sodium | 19 | $4,289 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 127 | $3,716 |
| Pregabalin | 129 | $3,502 |
| Gabapentin | 170 | $2,264 |
| Duloxetine Hcl | 105 | $1,996 |
| Tramadol Hcl ErTramadol Hcl | 31 | $1,974 |
| Celecoxib | 27 | $1,619 |
| Tizanidine Hcl | 34 | $1,560 |
| Chlorzoxazone | 33 | $1,491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $12,990 | $74,06545 claims |
| Collegium Pharmaceutical, Inc.Nucynta Er, Belbuca, Xtampza Er | $44 | $61,69060 claims |
| Hikma Pharmaceuticals USABuprenorphine | $32 | $10,70242 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Norfolk
- Lauren FeeneyNorfolk$17K
- Anna PrzybylskaNorfolk$13K
- Alycia DickensNorfolk$11K
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.